載入中
JPXHealthcareBiotechnology
最新資料
¥45.00
+¥2.00 · +4.65%
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
最新資料
¥45.00
+¥2.00 · +4.65%
盤中時間採用JST。市場資料可能有所延遲。
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
日內區間
目前¥45.00
52週區間
目前¥45.00
盤中時間採用JST。市場資料可能有所延遲。
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
日內區間
目前¥45.00
52週區間
目前¥45.00
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（JPY） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 8.4萬 JPY | 113.3萬 JPY | 7.2萬 JPY | 528萬 JPY | 1540.8萬 JPY |
| 銷貨成本 | 2.9萬 JPY | 3.2萬 JPY | 41.3萬 JPY | 1861.4萬 JPY | 3844萬 JPY |
| 毛利 | 5.5萬 JPY | 110.1萬 JPY | −34.1萬 JPY | −1333.4萬 JPY | −2303.2萬 JPY |
| 研究與開發 | — | 8.88億 JPY | 7.76億 JPY | 11.68億 JPY | 11.36億 JPY |
| 銷售、一般及管理費用 | 12.95億 JPY | 2.74億 JPY | 3.79億 JPY | 2.85億 JPY | 3.17億 JPY |
| 營業費用 | 12.95億 JPY | 11.62億 JPY | 11.55億 JPY | 14.54億 JPY | 14.53億 JPY |
| 利息收入 | 1.6萬 JPY | 6.9萬 JPY | 1.2萬 JPY | 2萬 JPY | 2.7萬 JPY |
| 利息支出 | — | — | — | 6.1萬 JPY | 36.2萬 JPY |
| 折舊和攤銷 | — | — | 39.5萬 JPY | 1671.9萬 JPY | 3512.3萬 JPY |
| 營業利益 | −12.95億 JPY | −11.61億 JPY | −11.55億 JPY | −14.67億 JPY | −14.76億 JPY |
| 淨利 | −13.05億 JPY | −11.51億 JPY | −11.68億 JPY | −14.86億 JPY | −14.84億 JPY |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
